Literature DB >> 8186198

Transforming growth factor-beta inhibits IL-4 and IFN-gamma production by stimulated human T cells.

W Holter1, F S Kalthoff, W F Pickl, C Ebner, O Majdic, D Kraft, W Knapp.   

Abstract

The present study investigates the effect of transforming growth factor (TGF)-beta on the production of IL-4 and IFN-gamma by the leukemia Th0 type cell line HUT78, by freshly isolated human T cells, and by antigen specific human T cell clones. We found that IL-4 and IFN-gamma, but not IL-2, production by stimulated HUT78 cells was inhibited by TGF-beta 1. TGF-beta 1 also reduced the accumulation of IL-4 and IFN-gamma specific mRNA in stimulated HUT78 cells. However, IL-2 and IL-7 co-stimulated IL-4 and IFN-gamma production, whereas IL-1, IL-3, IL-5, IL-6, IL-8, tumor necrosis factor-alpha or granulocyte macrophage colony stimulating factor had no effect. Because IL-2 is an important helper cytokine for the production of IL-4 and IFN-gamma, we investigated whether signal transduction through the IL-2 receptor is impaired by TGF-beta 1. We found that tyrosine phosphorylation in response to IL-2 in HUT78 cells was strongly inhibited by a short preincubation with TGF-beta 1. Evidence for an antagonistic role for TGF-beta 1 and IL-2 comes from the finding that high doses of IL-2 could partially overcome TGF-beta 1 mediated inhibition of IL-4 and IFN-gamma production. Similar to its effect on HUT78 cells, TGF-beta 1 also inhibited IL-4 and IFN-gamma production by freshly isolated T cells as well as by human T cell clones. Taken together, our experiments show that the IL-2 dependent cytokines IL-4 and IFN-gamma are both negatively controlled by TGF-beta under conditions where IL-2 production is unaffected by a mechanism which partially involves an inhibition of IL-2/IL-2R signal transduction. These data identify TGF-beta and IL-2 as mutual antagonists in the regulation of IL-4 and IFN-gamma production.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8186198     DOI: 10.1093/intimm/6.3.469

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  Regulation of cytokine production by human Th0 cells following stimulation with peptide analogues: differential expression of TGF-beta in activation and anergy.

Authors:  D C Tsitoura; C M Gelder; D M Kemeny; J R Lamb
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

Review 2.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Authors:  Annie A Wu; Virginia Drake; Huai-Shiuan Huang; ShihChi Chiu; Lei Zheng
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

3.  Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma.

Authors:  Krisztian Nemeth; Andrea Keane-Myers; Jared M Brown; Dean D Metcalfe; James D Gorham; Jared D Gorham; Virgilio G Bundoc; Victor G Bundoc; Marcus G Hodges; Ivett Jelinek; Satish Madala; Sarolta Karpati; Eva Mezey
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

4.  High-level IL-10 production by monoclonal antibody-stimulated human T cells.

Authors:  M Schwarz; O Majdic; W Knapp; W Holter
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

5.  Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor beta by treatment with bleomycin.

Authors:  L Yuan; Y Kuramitsu; Y Li; M Kobayashi; M Hosokawa
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968

6.  Inhibition of Mycobacterium bovis BCG-induced tumor necrosis factor alpha secretion in human cells by transforming growth factor beta.

Authors:  P Méndez-Samperio; M Hernandez-Garay; A Nuñez Vazquez
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

7.  Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-β1.

Authors:  A E Anderson; D J Swan; O Y Wong; M Buck; O Eltherington; R A Harry; A M Patterson; A G Pratt; G Reynolds; J-P Doran; J A Kirby; J D Isaacs; C M U Hilkens
Journal:  Clin Exp Immunol       Date:  2016-11-02       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.